A Study of SPY002-072 in Healthy Volunteers

ConditionHealthy

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-60

SponsorSpyre Therapeutics, Inc.

About this trial

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

Eligibility criteria

Qualifiers

Healthy men and women

Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Disqualifiers

Participation in more than one cohort

Evidence of clinically significant abnormality or disease

Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent

History of severe allergic reactions or hypersensitivity